Patent intelligence · US
US 10548964
Antigens and vaccines directed against human enteroviruses
Antigens and vaccines directed against human enteroviruses
Patent details — US 10548964
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 4, 2020
- Expiration
- Jan 30, 2040
- Applicant
- SENTINEXT THERAPEUTICS Sdn Bhd
- Claims
- 9
- CPC classes
- A61K, A61K2039/5256, A61K2039/5258, A61K2039/70
Quick answer
US 10548964 (Antigens and vaccines directed against human enteroviruses) is held by SENTINEXT THERAPEUTICS Sdn Bhd. Status: granted. Granted Feb 4, 2020. Expires Jan 30, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SENTINEXT THERAPEUTICS Sdn Bhd
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K2039/5256, A61K2039/5258, A61K2039/70, A61K39/12, A61K39/125
More from SENTINEXT THERAPEUTICS Sdn Bhd
Related pharmaceutical patents in our USPTO index.
-
US 12419895
Methods for treating subjects with Prader-Willi syndrome
granted -
US 12350258
Compositions and methods for treatment of skin-related diseases and promoting dermatological health
granted -
US 12343348
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12343381
Dosage regimen for pegylated interferon
granted -
US 12178823
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12109216
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12005081
Chimeric receptors and methods of use thereof
granted -
US 11884656
Pyrrole derivatives as PLK1 inhibitors
granted
Frequently asked questions
What is US patent 10548964?
US 10548964 (Antigens and vaccines directed against human enteroviruses) is held by SENTINEXT THERAPEUTICS Sdn Bhd. Status: granted. Granted Feb 4, 2020. Expires Jan 30, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10548964?
SENTINEXT THERAPEUTICS Sdn Bhd is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 95 pharmaceutical patents for this assignee.
When does US 10548964 expire?
Our index shows an expiration date of Jan 30, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.